Low lymphocyte-to-monocyte ratio is associated with an enhanced regulatory t lymphocyte function in metastatic cancer patients
Despite their different mechanism of action, the antitumor efficacy of overall anticancer therapies would depend not only on their antitumor cytotoxic activity, but also on the immune biological response of cancer patients, which is the result of interactions between immunostimulatory and immunosuppressive events. Today, it is known that the anticancer immunity is mainly depending on T helper (TH) (CD4+) and dendritic cells, whereas it inhibited by the macrophage system and regulatory T lymphocytes (T reg) (CD4+CD25+).